IMRX
Immuneering CorpKey Statistics
About Immuneering Corp
Immuneering Corp (IMRX) is a pioneering biotechnology firm dedicated to advancing therapeutics for cancer and other severe conditions through its proprietary drug discovery platforms. By leveraging state-of-the-art bioinformatics and machine learning capabilities, Immuneering focuses on identifying and optimizing drug candidates that target essential biological pathways, ultimately aiming to enhance patient outcomes with reduced toxicity profiles. With a robust pipeline of innovative therapies and strategic collaborations in place, the company is well-positioned to excel in the rapidly evolving landscape of personalized medicine and targeted oncology, presenting substantial growth opportunities for institutional investors.
Fundamentals
| Revenue (TTM) | 455 |
| Gross Profit (TTM) | 158,830 |
| EBITDA | $-58.88M |
| Operating Margin | 0.00% |
| Return on Equity | -43.80% |
| Return on Assets | -27.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.38 |
| Price-to-Book | 1.69 |
| Price-to-Sales (TTM) | 563.62 |
| EV/Revenue | 191913.54 |
| EV/EBITDA | -1.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | $64.70M |
| Float | $49.44M |
| % Insiders | 17.81% |
| % Institutions | 47.17% |
Historical Volatility
Volatility is currently contracting